Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
07:00am, Wednesday, 01'st Apr 2026
BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today a
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
02:46am, Wednesday, 25'th Mar 2026
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the stock, MarketBeat repor
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
05:24pm, Friday, 20'th Mar 2026
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
11:21am, Wednesday, 18'th Mar 2026
Adviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction value $71.01 million based on quarterly average price. The quarter-end value of position dropped by $65.05 million, refl
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 09'th Mar 2026
BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today a
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
04:37pm, Monday, 02'nd Mar 2026
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
02:20am, Saturday, 28'th Feb 2026
Shares of Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fourteen research firms that are covering the company, MarketBeat.c
Ocular Therapeutix Shares Jump After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD
03:13am, Tuesday, 24'th Feb 2026
Ocular Therapeutix (NASDAQ: OCUL) reported positive top-line results from its SOL-1 Phase 3 clinical trial evaluating AXPAXLI (also referred to as OTX-TKI) in wet age-related macular degeneration (wet
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 9.5% – Time to Buy?
03:26am, Sunday, 22'nd Feb 2026
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report)'s share price was up 9.5% during mid-day trading on Friday. The stock traded as high as $7.20 and last traded at $7.6970. Approximately 504,36
San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigatio
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
01:04pm, Wednesday, 18'th Feb 2026
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigation focuses on Ocul
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
04:15pm, Tuesday, 17'th Feb 2026
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
Stock Market Today: Dow, Nasdaq, S&P 500 Futures Drop— ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (UPDATED)
08:38am, Tuesday, 17'th Feb 2026
U.S. stock futures fluctuated on Tuesday following Friday's mixed close. Futures of major benchmark indices were mixed at the beginning of the holiday-shortened week as the markets were closed on Mond
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
07:08am, Tuesday, 17'th Feb 2026
Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
07:00am, Tuesday, 17'th Feb 2026
BEDFORD, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today an
